Modulation of PKCα/ETS1 by klotho restores CYB5R4-dependent mitochondrial function in proximal tubular epithelial cells to attenuate the progression of diabetic kidney disease
简介:
- 作者: Chun Gan, Xindi Zhou, Lan Qiu, Dan Chen, Yulu Shi, Qing Yang, Huimin Jiang, Han Xiao, Wanbing Chen, Xuejun Yang, Yaxi Chen, Mo Wang, Haiping Yang, Wei Jiang, Qiu Li
- 杂志: Cardiovascular Diabetology
- Doi: https://www.doi.org/10.1186/s12933-026-03150-y
- 出版日期: 2026/3/28
摘要
Objective
Diabetic kidney disease (DKD) progression involves early proximal tubular injury, which precedes podocyte injury. The protective role of the protein Klotho in DKD is well-documented, but its impact on early tubular injury and mitochondrial dysfunction in proximal tubule epithelial cells (PTECs) remains underexplored. This study aimed to determine whether Klotho alleviates DKD by targeting mitochondrial dysfunction in PTECs and to uncover the molecular mechanisms involved.
Methods
The role of Klotho was investigated using human kidney biopsies from patients at different DKD stages and a diabetic mouse model (induced by high-fat diet and streptozotocin). In vivo and in vitro techniques, including immunofluorescence, Western blot, transmission electron microscopy, and single-cell RNA sequencing, were used to assess tubular injury, mitochondrial integrity, and key protein interactions. The function of a newly identified protein, CYB5R4, was validated using knockdown and overexpression approaches in mouse models and human kidney (HK-2) cells.
Results
Our results reveal a novel molecular pathway where Klotho alleviates early tubular injury in DKD by targeting the mitochondrial protein CYB5R4. We demonstrate that CYB5R4 is critically downregulated in DKD and that its restoration is both necessary and sufficient for Klotho's protective effect on mitochondrial function in PTECs. This regulation follows a defined signaling cascade where Klotho suppresses PKCα, which in turn inhibits the transcription factor ETS1. This inhibition of ETS1 leads to the de-repression of the CYB5R4 promoter, ultimately reducing tubular apoptosis and injury. This CYB5R4-dependent mechanism positions CYB5R4 as a key therapeutic target.
Conclusion
Our findings uncover a novel Klotho/PKCα/ETS1/CYB5R4 signaling axis in PTECs that restores mitochondrial function and mitigates DKD progression, offering a promising therapeutic target for managing DKD.
关于派真
作为一家专注于AAV 技术十余年，深耕基因治疗领域的CRO&CDMO，派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付，我们为全球客户提供一站式CMC解决方案，包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台，我们能将AAV产量提高多至10倍，每批次产量可达1×10¹⁷vg，以满足多样化的商业化和临床项目需求。此外，我们定制化的mRNA和脂质纳米颗粒（LNP）产品及服务覆盖药物和疫苗开发的各个阶段，从研发到符合GMP的生产，提供端到端的一站式解决方案。
